Based on the Viking Therapeutics Inc stock forecast from 12 analysts, the average analyst target price for Viking Therapeutics Inc is USD 110.70 over the next 12 months. Viking Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Viking Therapeutics Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Viking Therapeutics Inc’s stock price was USD 49.58. Viking Therapeutics Inc’s stock price has changed by -27.60% over the past week, -23.27% over the past month and +339.93% over the last year.
No recent analyst target price found for Viking Therapeutics Inc
No recent average analyst rating found for Viking Therapeutics Inc
Company Overview Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. Read Less
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroi...Read More
Frequently Asked Questions About Viking Therapeutics Inc (VKTX) Stock
Based on ratings from 12 analysts Viking Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 23 buy, sell and hold ratings.
Unfortunately we do not have enough data on VKTX's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for VKTX is USD 110.70 over the next 12 months. The maximum analyst target price is USD 164 while the minimum anlayst target price is USD 80.
Unfortunately we do not have enough data on VKTX's stock to indicate if its overvalued.
The last closing price of VKTX's stock was USD 49.58.
The most recent market capitalization for VKTX is USD 5.52B.
Based on targets from 12 analysts, the average taret price for VKTX is projected at USD 110.70 over the next 12 months.
This means that VKTX's stock price may go up by +123.27% over the next 12 months.
We can't find any ETFs which contains Viking Therapeutics Inc's stock.
As per our most recent records Viking Therapeutics Inc has 30 Employees.
Viking Therapeutics Inc's registered address is 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121.
You can get more information about it from Viking Therapeutics Inc's website at https://www.vikingtherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Viking Therapeutics Inc (VKTX) Stock
Based on ratings from 12 analysts Viking Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 23 buy, sell and hold ratings.
Unfortunately we do not have enough data on VKTX's stock to indicate if its a good dividend stock.
Based on targets from 12 analysts, the average taret price for VKTX is USD 110.70 over the next 12 months. The maximum analyst target price is USD 164 while the minimum anlayst target price is USD 80.
Unfortunately we do not have enough data on VKTX's stock to indicate if its overvalued.
The last closing price of VKTX's stock was USD 49.58.
The most recent market capitalization for VKTX is USD 5.52B.
Based on targets from 12 analysts, the average taret price for VKTX is projected at USD 110.70 over the next 12 months.
This means that VKTX's stock price may go up by +123.27% over the next 12 months.
We can't find any ETFs which contains Viking Therapeutics Inc's stock.
As per our most recent records Viking Therapeutics Inc has 30 Employees.
Viking Therapeutics Inc's registered address is 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121.
You can get more information about it from Viking Therapeutics Inc's website at https://www.vikingtherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VKTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
